P/B
0,5
Quanterix
Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.
Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.
$119.2M
Market Cap • 9/11/2026
2007
(19 years)
Founded
2017
(9 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
0,8
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
5,1
EPS
—
Market Cap
Market Cap
119,2M
EV
59M
EV/Revenue
0,4
EV/EBITDA
-0,5
EV/EBIT
-0,4
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
0%
Total Yield
0%
Payout
0%
Retained Earnings
-643,7M
Profitability
Gross Margin
42,7%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
20,8%
Capex/Revenue
0,5%
Capex/D&A
3,3%
Capex/OCF
-0,9%
SBC/OCF
—
% PPE
11%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
6,9%
CAGR Op. Income 5Y
37,5%
CAGR Net Income 5Y
33%
CAGR EPS 5Y
24,8%
CAGR OCF 5Y
24,9%
Leverage
N.D./EBITDA
0,5
Debt/Equity
0%
Current Ratio
3,4
Quick Ratio
2,3
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!